taurine and Melanoma
taurine has been researched along with Melanoma in 14 studies
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"The efficacy and tolerability of taurolidine, an antibacterial substance, was evaluated in a phase 2 trial enrolling patients with advanced melanoma." | 9.15 | The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. ( Baumann, K; Dummer, R; French, LE; Goldinger, SM; Imhof, L; Röthlisberger, P; Schad, K, 2011) |
" In this study, we investigated the antimelanogenic activity of combination of AZ and taurine (Tau) in B16F10 mouse melanoma cells." | 7.76 | Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells. ( Kim, AK; Yu, JS, 2010) |
"This study evaluates whether taurolidine, a novel antibiotic agent, induces murine melanoma cell apoptosis in vitro and in vivo." | 7.74 | Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. ( Gong, SL; Liu, LL; Redmond, HP; Sun, BS; Wang, JH, 2007) |
"The efficacy and tolerability of taurolidine, an antibacterial substance, was evaluated in a phase 2 trial enrolling patients with advanced melanoma." | 5.15 | The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. ( Baumann, K; Dummer, R; French, LE; Goldinger, SM; Imhof, L; Röthlisberger, P; Schad, K, 2011) |
" In this study, we investigated the antimelanogenic activity of combination of AZ and taurine (Tau) in B16F10 mouse melanoma cells." | 3.76 | Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells. ( Kim, AK; Yu, JS, 2010) |
"This study evaluates whether taurolidine, a novel antibiotic agent, induces murine melanoma cell apoptosis in vitro and in vivo." | 3.74 | Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. ( Gong, SL; Liu, LL; Redmond, HP; Sun, BS; Wang, JH, 2007) |
"In human donor samples (4 melanoma-affected eyes, and 14 control eyes; age range, 62-93 years), radiochemical techniques were used to determine the RPE taurine accumulation at various exogenous concentrations." | 3.72 | Taurine uptake by human retinal pigment epithelium: implications for the transport of small solutes between the choroid and the outer retina. ( Cunningham, JR; Hillenkamp, J; Hussain, AA; Jackson, TL; Marshall, J, 2004) |
"Forty-seven patients with metastatic malignant melanoma took part in a phase II trial of tauromustine (TCNU), a new chlorethylnitrosourea based on the endogenous amino acid taurine." | 3.67 | Phase II study of tauromustine in disseminated malignant melanoma. ( Bergh, J; Blomquist, E; Gjedde, SB; Lindegaard-Madsen, E; Mouridsen, HT; Nolte, H, 1989) |
"The antitumor activity of 2-[bis-(2-chloroethyl)-amino]ethanesulfonic acid (also referred to here as "taurine mustard" or "taumustine") was evaluated in the murine P388 and L1210 lymphocytic leukemias and in the pigmented and nonpigmented B16 melanoma systems." | 3.67 | Modulation by taurine of the toxicity of taumustine, a compound with antitumor activity. ( Fisher, JM; Pierson, HF; Rabinovitz, M, 1985) |
"Glycine has been well characterized in spinal cord as an inhibitory neurotransmitter which activates a glycine-gated chloride channel (GlyR) expressed in postsynaptic membranes." | 2.40 | Glycine: a new anti-inflammatory immunonutrient. ( Bradford, B; Enomoto, N; Ikejema, K; Rose, ML; Rusyn, I; Schemmer, P; Seabra, V; Stacklewitz, RF; Thurman, RG; Wheeler, MD; Yin, M; Zhong, Z, 1999) |
Research
Studies (14)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (28.57) | 18.7374 |
1990's | 4 (28.57) | 18.2507 |
2000's | 4 (28.57) | 29.6817 |
2010's | 2 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Yu, JS | 1 |
Kim, AK | 1 |
Imhof, L | 1 |
Goldinger, SM | 1 |
Baumann, K | 1 |
Schad, K | 1 |
French, LE | 1 |
Röthlisberger, P | 1 |
Dummer, R | 1 |
Shrayer, DP | 1 |
Lukoff, H | 1 |
King, T | 1 |
Calabresi, P | 1 |
Hillenkamp, J | 1 |
Hussain, AA | 1 |
Jackson, TL | 1 |
Cunningham, JR | 1 |
Marshall, J | 1 |
Sun, BS | 1 |
Wang, JH | 1 |
Liu, LL | 1 |
Gong, SL | 1 |
Redmond, HP | 1 |
Braumann, C | 1 |
Jacobi, CA | 1 |
Rogalla, S | 1 |
Menenakos, C | 1 |
Fuehrer, K | 1 |
Trefzer, U | 1 |
Hofmann, M | 1 |
Gjedde, SB | 3 |
Mouridsen, HT | 3 |
L-Madsen, E | 2 |
Jensen, NV | 2 |
Blomquist, E | 3 |
Bergh, J | 3 |
Söderberg, M | 2 |
Wählby, S | 2 |
Wheeler, MD | 1 |
Ikejema, K | 1 |
Enomoto, N | 1 |
Stacklewitz, RF | 1 |
Seabra, V | 1 |
Zhong, Z | 1 |
Yin, M | 1 |
Schemmer, P | 1 |
Rose, ML | 1 |
Rusyn, I | 1 |
Bradford, B | 1 |
Thurman, RG | 1 |
Glover, DJ | 1 |
Nolte, H | 1 |
Lindegaard-Madsen, E | 1 |
Smyth, JF | 1 |
Gundersen, S | 1 |
Renard, J | 1 |
Pinedo, HM | 1 |
Pierson, HF | 1 |
Fisher, JM | 1 |
Rabinovitz, M | 1 |
Vester, F | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481] | Phase 2 | 13 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to Some of the researchers finished their participation in the study.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Changes in Serum Concentration of Inflammatory Biomarkers (TNF-alpha)
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
Intervention | log (percent change) (Mean) |
---|---|
Glycine | -0.3908 |
Placebo | 0.2035 |
Changes in Sputum Concentration of Inflammatory Biomarkers (G-CSF)
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
Intervention | log (percent change) (Mean) |
---|---|
Glycine | -0.0819 |
Placebo | 0.1668 |
Changes in Sputum Concentration of Inflammatory Biomarkers (IL-6)
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
Intervention | log (percent change) (Mean) |
---|---|
Glycine | -0.00007 |
Placebo | 0.1739 |
Changes in Clinical Data Scores (Other Than Sputum Production, Dyspnea and Global Symptoms)
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
Intervention | Percentage of baseline (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Cough questionnaire score | Appetite questionnaire score | Energy questionnaire score | Body weight | Height | Heart rate | Respiratory rate | Temperature | |
Glycine | 81.1 | 89.1 | 84.6 | 101.6 | 100.5 | 103.5 | 94.8 | 100.0 |
Placebo | 89.1 | 132.1 | 111.5 | 103.6 | 100.5 | 98.1 | 109.0 | 100.1 |
Changes in FEV1, FEF25, and FEFmax
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
Intervention | Percentage of baseline (Mean) | ||
---|---|---|---|
Forced expiratory volume at first second (FEV1) | Forced expiratory flow at 25%FVC (FEF25) | Maximal forced expiratory flow (FEFmax, PEFR) | |
Glycine | 109.7 | 133.9 | 115.3 |
Placebo | 91.4 | 83.3 | 91.2 |
Changes in Other Spirometric Variables
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
Intervention | Percentage of baseline (Mean) | |
---|---|---|
Forced vital capacity (FVC) | Forced expiratory flow at 75%FVC (FEF75) | |
Glycine | 104.1 | 111.8 |
Placebo | 100.6 | 108.9 |
Changes in Pulse Oximetry, FEV1/FVC, and FEF50.
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
Intervention | Percentage of baseline (Mean) | ||
---|---|---|---|
Peripheral oxygen saturation (SpO2) | FEV1/FVC | Forced expiratory flow at 50%FVC (FEF50) | |
Glycine | 105.2 | 105.2 | 115.5 |
Placebo | 98.9 | 94.9 | 93.1 |
Changes in Score for Sputum Production, Dyspnea and Global Symptoms
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
Intervention | Percentage of baseline (Mean) | ||
---|---|---|---|
Sputum questionnaire score | Dyspnea questionnaire score | Total questionnaire score | |
Glycine | 82.0 | 75.6 | 77.7 |
Placebo | 102.6 | 103.8 | 98.7 |
Changes in Serum Concentration of Inflammatory Biomarkers (Other Than TNF-alpha)
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
Intervention | log (percent change) (Mean) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Myeloperoxidase | IL-1 | IL-4 | IL-6 | IL-7 | IL-8 | IL-12 | IL-13 | G-CSF | IFN-gamma | MCP-1 | MIP-1beta | |
Glycine | -0.4361 | -0.1635 | 0.2964 | 0.0085 | 0.0356 | -0.1466 | 0.3203 | -0.0561 | -0.0776 | 0.3272 | -0.0836 | 0.0330 |
Placebo | -0.2906 | -0.0352 | 0.1470 | 0.2255 | 0.0819 | -0.2364 | 0.2603 | 0.1953 | 0.2272 | 0.3639 | 0.0472 | -0.0608 |
Changes in Sputum Concentration of Inflammatory Biomarkers (Other Than IL-6 and G-CSF)
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
Intervention | log (percent change) (Mean) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Myeloperoxidase | IL-1 | IL-2 | IL-4 | IL-5 | IL-7 | IL-8 | IL-10 | IL-12 | IL-13 | IL-17 | IFN-gamma | MCP-1 | MIP-1beta | TNF-alpha | GM-CSF | |
Glycine | 0.1294 | -0.0918 | 0.0233 | -0.0161 | 0.2498 | 0.0611 | -0.0824 | 0.0549 | 0.1675 | 0.1630 | 0.0680 | 0.0248 | 0.0042 | -0.0303 | 0.0412 | -0.0538 |
Placebo | 0.0669 | -0.0102 | -0.0274 | 0.0522 | 0.1304 | 0.1387 | 0.0542 | 0.0074 | 0.0677 | 0.0953 | 0.1140 | 0.0649 | 0.2608 | 0.0977 | 0.1568 | -0.0822 |
Reviews
1 review available for taurine and Melanoma
Article | Year |
---|---|
Glycine: a new anti-inflammatory immunonutrient.
Topics: Alcohols; Animals; Anti-Inflammatory Agents; Calcium Channels, L-Type; Chloride Channels; Cyclospori | 1999 |
Trials
4 trials available for taurine and Melanoma
Article | Year |
---|---|
The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study.
Topics: Adult; Aged; Anti-Infective Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 2011 |
Phase II study of tauromustine in disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compoun | 1994 |
Phase I study of tauromustine administered in a weekly schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Huma | 1993 |
Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Ni | 1989 |
Other Studies
9 other studies available for taurine and Melanoma
Article | Year |
---|---|
Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells.
Topics: Animals; Cell Line, Tumor; Dicarboxylic Acids; Drug Combinations; Humans; Melanins; Melanocytes; Mel | 2010 |
The effect of Taurolidine on adherent and floating subpopulations of melanoma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Drug Screening Assays, Antitumor; Humans; Mel | 2003 |
Taurine uptake by human retinal pigment epithelium: implications for the transport of small solutes between the choroid and the outer retina.
Topics: Aged; Aged, 80 and over; Aging; Binding, Competitive; Biological Transport; Carrier Proteins; Case-C | 2004 |
Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Survi | 2007 |
The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model.
Topics: Animals; Antineoplastic Agents; Body Weight; Dose-Response Relationship, Drug; Female; Injections, I | 2007 |
New approaches to the chemotherapy of melanoma.
Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 1991 |
Phase II study of tauromustine in disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Humans; Melanoma; Middle Aged; Nitr | 1989 |
Modulation by taurine of the toxicity of taumustine, a compound with antitumor activity.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Female; Leukemia L1210; Leukemia P388; Male; Melano | 1985 |
Amino acid pattern and malignant growth.
Topics: Amino Acids; Animals; Antineoplastic Agents; Arginine; Fishes; Histones; In Vitro Techniques; Melano | 1965 |